Department of Hepatobiliary Surgery, West Campus, Beijing Chao-yang Hospital Affiliated to Capital Medical University, Beijing, China.
Surgery. 2013 Jan;153(1):78-85. doi: 10.1016/j.surg.2012.06.004. Epub 2012 Jul 31.
We aimed to assess the feasibility, safety, and efficacy of radiofrequency (RF) ablation for the treatment of large (≥5 cm in greatest diameter) hepatic hemangiomas.
Thirty-six patients (15 male, 21 female; mean age 50 years) with 41 hepatic hemangiomas ≥5 cm in diameter were enrolled and treated with RF ablation attributable to the presence of enlargement tendency and/or persistent hemangioma-associated symptoms. Twenty patients had 24 hemangiomas <10 cm, and 16 patients had 17 hemangiomas ≥10 cm. Technical success, complications related to RF ablation, completed ablation, symptom relief, change in size of ablation zone, and recurrence of the residual tumor were analyzed.
Of the 41 hemangiomas with a mean diameter 10 ± 4 cm (range, 5-22 cm), 26 subcapsular lesions were treated with a laparoscopic approach, and 15 lesions located in liver parenchyma underwent a computed tomography-guided percutaneous approach. RF ablation was performed successfully in all patients. There were 62 complications related to the ablation in 22 patients, including 6 of 20 patients with hemangiomas <10 cm and all the 16 patients with hemangiomas ≥10 cm. According to the Dindo-Clavien classification, 2 complications (lower esophageal fistula and acute respiratory distress syndrome, Grade III and Grade IV, respectively) were major in 2 patients with hemangiomas ≥10 cm; all the other were minor in 20 patients (Grade I). All the complications were recovered by conservative treatment. Thirty-eight (93%) of 41 hepatic hemangiomas were ablated completely, including all the 24 lesions <10 cm and 14 of 17 lesions ≥10 cm. All the symptoms related to hemangiomas disappeared (n = 22) or were ameliorated (n = 4) after ablation. The mean diameter of ablation zone was decreased to 6 ± 3 cm (2-12 cm) in a mean follow-up period (X ± SD) of 15 ± 6 months (range, 6-24 months), without recurrence or enlargement of the 3 residual tumors.
The present study supports RF ablation as an alternative treatment for hepatic hemangiomas ≥5 cm (but smaller than 10 cm) for the low risk of complications and likelihood of complete ablation, but, in contrast, RF ablation appears to be an inappropriate method for hepatic hemangiomas ≥10 cm because of the high occurrence rate of complications.
评估射频(RF)消融治疗大(最大直径≥5cm)肝血管瘤的可行性、安全性和疗效。
36 例患者(男 15 例,女 21 例;平均年龄 50 岁)共 41 个肝血管瘤,直径≥5cm,因有增大趋势和/或持续血管瘤相关症状而接受 RF 消融治疗。20 例患者有 24 个血管瘤<10cm,16 例患者有 17 个血管瘤≥10cm。分析技术成功率、与 RF 消融相关的并发症、完成消融、症状缓解、消融区大小变化和残余肿瘤复发情况。
41 个血管瘤的平均直径为 10±4cm(范围 5-22cm),其中 26 个位于肝包膜下的病变采用腹腔镜方法治疗,15 个位于肝实质内的病变采用 CT 引导下经皮方法治疗。所有患者均成功完成 RF 消融。22 例患者共发生 62 例与消融相关的并发症,其中 20 例<10cm 的血管瘤患者中有 6 例,16 例≥10cm 的血管瘤患者均有并发症。根据 Dindo-Clavien 分级,2 例(分别为食管下瘘和急性呼吸窘迫综合征,分别为 3 级和 4 级)严重并发症发生在 2 例≥10cm 的血管瘤患者中;其余 20 例均为轻微并发症(1 级)。所有并发症均经保守治疗恢复。41 个肝血管瘤中 38 个(93%)完全消融,包括所有 24 个<10cm 的病变和 17 个≥10cm 的病变中的 14 个。消融后所有与血管瘤相关的症状均消失(n=22)或改善(n=4)。在平均随访时间(X±SD)为 15±6 个月(6-24 个月)后,消融区平均直径缩小至 6±3cm(2-12cm),3 个残余肿瘤无复发或增大。
本研究支持 RF 消融作为治疗直径≥5cm(但<10cm)肝血管瘤的一种替代方法,因其并发症风险低且完全消融的可能性大,但对于直径≥10cm 的肝血管瘤,RF 消融似乎是一种不合适的方法,因为其并发症发生率高。